Acute Alcohol Sensitivity

1. Disease Information

Overview. "Acute Alcohol Sensitivity" is the OMIM-recognized clinical phenotype produced by inherited deficiency of mitochondrial aldehyde dehydrogenase 2 (ALDH2), the enzyme that oxidizes acetaldehyde (the first, toxic metabolite of ethanol) to acetate. Loss-of-function of ALDH2 causes rapid systemic accumulation of acetaldehyde after even modest alcohol intake, producing a stereotyped acute reaction — facial/upper-body flushing, tachycardia, palpitations, nausea, headache, and malaise — commonly called the "alcohol flush reaction" or, colloquially, "Asian flush"/"Asian glow." It is one of the most common single-gene enzymopathies in humans, affecting an estimated ~540 million people, concentrated in East Asian populations (Chinese, Japanese, Korean) (Disease Models & Mechanisms review).

Key identifiers: - OMIM Phenotype: #610251 — ALCOHOL SENSITIVITY, ACUTE (OMIM #610251) - OMIM Gene: 100650 — ALDEHYDE DEHYDROGENASE 2; ALDH2 (12q24.12) - MONDO: MONDO:0012454 (Malacards) - NIH Genetic Testing Registry condition: C2674838 (GTR) - ClinVar variant-condition record: NM_000690.4(ALDH2):c.1510G>A (p.Glu504Lys) associated with "Alcohol sensitivity, acute" (ClinVar RCV000020058) - dbSNP: rs671 (the causal variant) - Related digenic disorder: AMeD syndrome* (OMIM #619151), caused by biallelic ADH5 variants plus the ALDH2 p.Glu504Lys allele (OMIM #619151; Oda et al., Sci Adv 2021, PMID:33355142)

Common synonyms: Alcohol flush reaction/syndrome; Asian flush; Asian glow; ALDH2 deficiency; ALDH2*2 deficiency; aldehyde dehydrogenase-2 deficiency; alcohol-induced flushing; "Oriental flushing syndrome" (older, non-preferred literature term).

Evidence basis. The evidentiary base is overwhelmingly aggregated, population-level and cohort/case-control human genetic epidemiology (large East Asian biobank and hospital cohorts, twin/family studies, GWAS), supplemented by mechanistic biochemistry/structural biology and mouse-model (ALDH2-knockout and ALDH2*2 knock-in) experimental data — not primarily individual patient EHR case reports, since this is a common polymorphism-driven trait rather than a rare monogenic disease discovered through isolated patients.

2. Etiology

Primary cause — genetic. Acute alcohol sensitivity is caused by the common East Asian-specific missense variant rs671 (c.1510G>A, p.Glu504Lys, historically "Glu487Lys" under older numbering) in ALDH2. This substitution sits at a subunit-interface within the small oligomerization domain of the ALDH2 homotetramer and destabilizes/inactivates the enzyme in a dominant-negative fashion: because ALDH2 functions as a tetramer, incorporation of even one mutant subunit disproportionately poisons the whole complex, so heterozygotes (~10–45% residual activity) and homozygotes (~1–5% residual activity) are both symptomatic, though homozygotes are far more severely affected (Larson et al., structural analysis; population activity data via selfdecode summary).

"The presence of the E487K subunit in ALDH2 decreases both the activity and stability of the heterotetramer in a dominant fashion... Since ALDH2 is a homotetrameric enzyme, random association of active and inactive subunits should generate about 6% normal tetramers, with the remainder containing at least 1 mutant subunit."

A second, less severe modifying/compounding factor is variation in ADH1B (alcohol dehydrogenase 1B, chromosome 4q23), the enzyme immediately upstream of ALDH2 that converts ethanol to acetaldehyde. The gain-of-function variant ADH1B*2 (rs1229984, Arg48His) accelerates ethanol→acetaldehyde conversion up to ~40-fold, so individuals carrying both fast ADH1B2 and slow ALDH22 experience the most rapid and severe acetaldehyde surges and flushing (review; selfdecode).

Risk factors: - Genetic: ALDH2 rs671 A allele (heterozygous or homozygous); co-inheritance of the fast-metabolizing ADH1B2 (rs1229984) allele amplifies the phenotype (PMC8312924). - Ancestry/environmental: East Asian ancestry (Han Chinese, Japanese, Korean) — the rs671 allele is essentially absent in African, European, and most Southeast Asian/Indian populations (DMM review). - Dose/behavioral:* Even modest alcohol intake precipitates symptoms; concomitant use of pharmacologic ALDH inhibitors (e.g., disulfiram, metronidazole, some cephalosporins, sulfonylureas) produces an analogous but pharmacologically-induced "disulfiram-alcohol reaction" that phenocopies the genetic condition (StatPearls Disulfiram; Wikipedia disulfiram-alcohol reaction).

Protective factors — genetic paradox. The very allele that causes the flush reaction is strongly protective against alcohol use disorder and alcoholic cirrhosis, because the aversive symptoms discourage heavy/habitual drinking:

"The ALDH2 rs671 GA/AA genotypes significantly reduced the risk of alcohol-induced mental disorders by 87%, alcohol dependence syndrome by 83%, and alcohol abuse by 66%." (Chang et al., Cancer Medicine 2023 review, PMC9844601)

Gene-environment interaction. The central G×E interaction of this condition is that the genotype is phenotypically silent without alcohol exposure — the enzyme deficiency only manifests acute symptoms and long-term tissue risk upon ethanol challenge. Critically, epidemiologic data show that the increased cancer risk conferred by ALDH2 deficiency is conditional on alcohol consumption:

"Among male weekly alcohol consumers, both flushing response and rs671 were associated with EC [esophageal cancer] risk, suggesting that the possession of inactive ALDH2 does not increase EC risk unless alcohol is consumed." (AACR CEBP)

Suggested CHEBI terms: CHEBI:16236 (ethanol), CHEBI:15343 (acetaldehyde), CHEBI:15366 (acetic acid), CHEBI:27897 (disulfiram).

3. Phenotypes

The acute reaction is a symptom cluster/behavioral+physiological syndrome, not a single defect, occurring within minutes to ~1 hour of alcohol ingestion.

Characteristics: - Onset: First alcohol exposure (often adolescence/young adulthood in cultures where alcohol is introduced socially); the reaction is present from the individual's very first drink and does not need to be "acquired." - Course: Acute, self-limited, episodic — recurs with every exposure to alcohol; not progressive as a standalone reaction, though repeated exposure across a lifetime is linked to cumulative tissue-damage risk (see Mechanism/Prognosis). - Severity/penetrance: Highly genotype-dependent — ALDH22 homozygotes show near-complete flushing penetrance and the most severe reaction; heterozygotes show a graded, often milder or inconsistent response, and can sometimes "drink through" the reaction with habituation (which does not reduce the underlying carcinogenic acetaldehyde exposure). - Frequency: In a Japanese cohort, "symptoms of facial flushing, palpitation, tachycardia, muscle weakness, headache and nausea present in nearly 43% of those with the deficiency" (search synthesis of Cancer Epidemiol Biomarkers Prev data). Genotype–phenotype concordance is high: "Blinded genotyping showed inactive ALDH2 for 94.4% of subjects who reported always flushing... whereas 95.6% of subjects reporting that they never exhibited facial flushing had active ALDH2" (PMID:9419411). - Quality of life:* Primarily social/behavioral — the reaction often leads to reduced or avoided alcohol consumption, with secondary social effects in cultures with strong drinking norms; a chronic downstream QoL burden accrues from increased skin flushing self-consciousness and (per §11/§2) elevated long-term cancer/cardiometabolic risk in those who drink despite the reaction.

4. Genetic / Molecular Information

Causal gene: ALDH2 (Aldehyde Dehydrogenase 2 Family Member; HGNC:404; OMIM *100650), chromosome 12q24.12, encoding the mitochondrial matrix tetrameric enzyme that oxidizes acetaldehyde to acetate using NAD⁺.

Primary pathogenic variant: - rs671, c.1510G>A, p.Glu504Lys (also historically numbered p.Glu487Lys, reflecting mature-protein vs. precursor numbering) — classified in ClinVar as pathogenic/associated with "Alcohol sensitivity, acute" (ClinVar RCV000020058). - Allele designations: ALDH2*1 (wild-type/active) vs. ALDH2*2 (rs671-A, inactive/hypomorphic). - Functional consequence: Dominant-negative loss-of-function via disruption of tetramer assembly/stability — not a simple recessive loss-of-function. Both GA heterozygotes (10–45% residual activity) and AA homozygotes (1–5% residual activity) are enzymatically deficient (search synthesis, gnomAD/functional summary). - Novel/rarer ALDH2 coding variants beyond rs671 causing additional acetaldehyde-accumulation phenotypes were recently catalogued: "Uncovering newly identified aldehyde dehydrogenase 2 genetic variants that lead to acetaldehyde accumulation after an alcohol challenge" (PMID:39075523, J Transl Med 2024).

Population/allele frequency: - rs671-A allele frequency: ~30–50% across East Asian populations (up to ~40% in Han Chinese and Japanese); minor allele frequency ~0.24 in Japanese (HapMap JPT), ~0.15 in Han Chinese (HapMap HCB); gnomAD/1000 Genomes-scale estimates give ~0.255 in East Asians versus ~0.0003 (essentially absent) outside East Asia (search synthesis; historical population survey). - Historically reported "absent ALDH2" activity frequencies ranged as high as 69% in some Indigenous Ecuadorian Highland populations down to 0% in Egyptian, Liberian, Kenyan, and European populations, though the East Asian-specific rs671 variant itself is the dominant, best-characterized cause in modern genomic data. - The allele is thought to have arisen from a single mutational event roughly 2,000–7,000 years ago in central China and spread with rice-domesticating agricultural populations ("Origin and Spread of the ALDH2 Glu504Lys Allele," PMC9590465) — a leading hypothesis is that it was positively selected as protection against alcohol-associated pathogens/toxicity or alcoholism in early agrarian society.

Modifier gene: ADH1B (4q23; HGNC:249), particularly rs1229984 (Arg48His, "ADH1B*2"), which increases the rate of ethanol-to-acetaldehyde conversion and synergistically worsens the flushing phenotype and downstream cancer risk when co-inherited with ALDH22. A second ADH1B variant (rs1042026 / "ADH1B3", predominantly in African-ancestry populations) has related but less-studied effects. ALDH2 rs674 is also examined alongside rs671 in some association studies.

Epigenetics/somatic: Not a classical epigenetic disease; however, acetaldehyde itself is a potent DNA-damaging agent (forms DNA adducts, induces sister chromatid exchange), and ALDH2 deficiency is mechanistically linked to accelerated acetaldehyde-DNA adduct accumulation in exposed tissues — this is the proposed causal chain for the elevated cancer risk (see Mechanism), rather than a primary epigenetic mechanism.

Chromosomal abnormalities: None reported; this is a single-nucleotide missense polymorphism, not a structural/copy-number disorder.

Related digenic disorder (molecular context): AMeD syndrome (Aplastic anemia, Mental retardation, and short stature, Digenic) arises when biallelic loss-of-function ADH5 (cytosolic formaldehyde dehydrogenase) variants co-occur with a heterozygous or homozygous ALDH2 p.Glu504Lys allele, causing loss of the combined formaldehyde-detoxification pathway (ADH5 + ALDH2), leading to bone marrow failure, developmental delay, and short stature — illustrating that ALDH2 deficiency's biochemical consequences extend beyond ethanol to endogenous aldehyde (formaldehyde) clearance (Oda et al. 2021, Sci Adv, PMID:33355142; OMIM #619151).

Suggested gene/ontology annotations: hgnc:404 (ALDH2), hgnc:249 (ADH1B); GO biological process GO:0006068 (ethanol catabolic process) / GO:0046185 (aldehyde catabolic process); GO molecular function GO:0004029 (aldehyde dehydrogenase [NAD+] activity). (IDs given from general ontology knowledge — verify canonical labels via OAK before curation.)

5. Environmental Information

• Primary environmental trigger: Ethanol (alcoholic beverage) ingestion — the sine qua non exposure; without alcohol the genotype is asymptomatic.
• Pharmacologic phenocopy triggers: ALDH-inhibiting drugs — disulfiram (classic), and reported "disulfiram-like reactions" with metronidazole, some first-generation sulfonylureas (chlorpropamide), and certain cephalosporins (e.g., cefotetan) — all of which produce the same acetaldehyde-accumulation flush/tachycardia syndrome by pharmacologically inhibiting ALDH activity (StatPearls).
• Lifestyle factors: Habitual drinking despite the reaction ("drinking through the flush") is a recognized risk-amplifying behavior — it does not reduce acetaldehyde exposure and is associated with substantially elevated cancer risk (§11).
• Occupational/endogenous aldehyde exposure: Because ALDH2 (with ADH5) also detoxifies endogenous and environmental formaldehyde, occupational or endogenous formaldehyde burden is a relevant compounding exposure in ALDH2-deficient individuals, most dramatically illustrated by AMeD syndrome.
• Infectious agents: Not applicable — this is not an infectious disease.

Suggested exposure ontology term: ECTO term for "exposure to ethanol" / "consumption of alcoholic beverage" (verify exact CURIE via OAK/ECTO lookup).

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular trigger: Alcohol ingestion → hepatic ADH1B-mediated oxidation of ethanol to acetaldehyde (normally a transient, rapidly-cleared intermediate).
2. Molecular lesion: In ALDH2*2 carriers, the p.Glu504Lys substitution destabilizes the ALDH2 homotetramer at the subunit interface, producing a dominant-negative loss of catalytic activity (10–45% residual in heterozygotes; 1–5% in homozygotes) (Structure paper).
3. Biochemical consequence: Acetaldehyde clearance is crippled → systemic acetaldehyde accumulation, reported up to 6-fold higher than in ALDH2-normal individuals after an equivalent alcohol challenge (search synthesis of PMC11288122 data).
4. Cellular/physiological effects: Acetaldehyde is a direct vasodilator and histamine-releasing agent, and stimulates sympathetic/catecholaminergic activity, producing cutaneous flushing (vasodilation), tachycardia/palpitations, and headache; acetaldehyde is also a reactive electrophile that forms protein and DNA adducts and generates reactive lipid-peroxidation byproducts such as 4-hydroxynonenal (4-HNE), compounding oxidative/genotoxic stress.
5. Organismal/clinical manifestation: Acute flush reaction (§3); chronically, repeated acetaldehyde/4-HNE exposure in those who continue to drink is mechanistically linked to:
6. Carcinogenesis — particularly esophageal squamous cell carcinoma, via direct acetaldehyde-DNA adduct formation in esophageal mucosa exposed to concentrated local ethanol/acetaldehyde ("field-cancerization" mechanism);
7. Cardiovascular pathology — 4-HNE/aldehyde-driven coronary vasospasm, endothelial dysfunction, and reported associations with hypertension, atrial fibrillation/left atrial substrate remodeling, and stroke;
8. Neurodegeneration — recent mechanistic work shows the rs671 variant enhances amyloid-β pathology: "(R)-4-HNE enantiomer adducts to residue Lys53 of C99 [APP], favoring Aβ40 generation in the Golgi apparatus," and lower ALDH2 activity is linked to reduced Aβ phagocytosis/clearance (Nat Commun 2024, PMID:38519490).
9. Formaldehyde-detoxification failure (AMeD syndrome arm) — since ALDH2 also participates in clearing endogenous formaldehyde generated by one-carbon/methanol metabolism, its loss (combined with ADH5 loss) causes hematopoietic stem cell genotoxic stress and bone marrow failure (PMID:33355142).

Cell types/tissues implicated: hepatocytes (primary site of ethanol/acetaldehyde metabolism), vascular smooth muscle and endothelial cells (flushing, coronary spasm), esophageal squamous epithelial cells (carcinogenesis), cardiac myocytes/fibroblasts (remodeling, AF), neurons/microglia/astrocytes (amyloid pathology), and hematopoietic stem/progenitor cells (AMeD syndrome).

Suggested GO terms: GO:0006068 ethanol catabolic process; GO:0006081 cellular aldehyde metabolic process; GO:0034599 cellular response to oxidative stress; GO:0006284 base-excision repair (DNA-adduct repair context). Suggested CL terms: CL:0000182 hepatocyte; CL:0002138 endothelial cell of vascular tree; CL:0000646 basal cell (esophageal epithelium context); CL:0000000-level cardiac myocyte term. Suggested CHEBI terms: CHEBI:15343 acetaldehyde; ~4-hydroxynonenal (verify CHEBI CURIE via OAK).

Molecular/omics profiling: No large-scale disease-specific transcriptomic/proteomic/metabolomic dataset exists specifically for "acute alcohol sensitivity" as a phenotype per se (it is a challenge-dependent, not a steady-state, condition), but targeted metabolomic studies quantify blood/breath acetaldehyde as the definitive biochemical readout after an ethanol or ethanol-patch challenge.

7. Anatomical Structures Affected

• Organ level (acute reaction): Skin/face/upper trunk (flushing), cardiovascular system (tachycardia, palpitations), CNS (headache).
• Organ level (chronic/secondary, in drinkers): Esophagus (squamous cell carcinoma), liver (metabolic first-pass organ), heart (arrhythmia/remodeling, especially atrial), brain (amyloid pathology/possible dementia risk), bone marrow (AMeD-syndrome arm only), and — per broader ALDH2-variance literature — stomach, breast, and ovary have been examined for genotype-cancer-risk associations.
• Body systems: Integumentary, cardiovascular, gastrointestinal, nervous, and (in the digenic AMeD arm) hematopoietic systems.
• Tissue/cell level: Vascular smooth muscle/endothelium (flushing, vasospasm); esophageal squamous epithelium (carcinogenesis target); cardiac conduction/atrial tissue; hepatic parenchyma.
• Subcellular level: Mitochondrial matrix (ALDH2 is a mitochondrial matrix enzyme — GO Cellular Component GO:0005759 mitochondrial matrix) is the primary organelle-level site of the molecular lesion.
• Localization/laterality: Bilateral, symmetric — flushing classically affects the face, neck, and upper chest bilaterally; not lateralized.

Suggested UBERON terms: UBERON:0001043 esophagus; UBERON:0002107 liver; UBERON:0000948 heart; UBERON:0001003 skin epidermis; UBERON:0002037 cerebellum/UBERON:0000955 brain (amyloid context).

8. Temporal Development

• Onset: From the individual's very first alcohol exposure — typically first noticed in adolescence or early adulthood coincident with initial social alcohol use; there is no "silent" pre-symptomatic period distinct from lack of exposure.
• Onset pattern: Acute — symptoms begin within minutes of alcohol ingestion (fast-ADH1B carriers can flush within minutes of the first sip) and typically resolve within 1–3 hours as acetaldehyde is eventually cleared by residual ALDH2 activity and alternate pathways.
• Progression/course: Episodic, fully recurrent with each exposure, not a progressive degenerative disease in itself. The acute episode is self-limited. However, the biological insult (acetaldehyde/4-HNE exposure) is cumulative across a lifetime of drinking episodes in those who continue to consume alcohol, driving the "stable-trait, cumulative-risk" pattern seen in long-term cancer/cardiovascular outcome studies.
• Habituation caveat: Some individuals report a diminished subjective flush response with repeated heavy drinking ("drinking through" the reaction), but this reflects tolerance to the symptom, not to the underlying enzymatic deficiency or the carcinogenic acetaldehyde exposure — an important clinical/public-health distinction (see "Beyond the Flush: Reframing ALDH2 Deficiency as a Public Health Risk," Karger Public Health Genomics).
• Remission: No spontaneous remission of the genetic trait; the only "remission" is behavioral abstinence from alcohol/ALDH-inhibiting drugs.
• Critical periods: Adolescent/young-adult introduction to alcohol is a socially critical period, since the phenotype often (but not always) leads to early avoidance behavior that is protective against later alcohol use disorder.

9. Inheritance and Population

• Inheritance pattern: Autosomal, with a dominant-negative functional mechanism — both heterozygotes and homozygotes for ALDH22 (rs671-A) manifest the flushing phenotype, though homozygotes show more complete enzyme inactivation and more severe/consistent symptoms. This is best described as semi-dominant/dose-dependent* rather than classical Mendelian dominant or recessive.
• Penetrance: High but not complete for the flush phenotype (heterozygote flushing is reported in a substantial majority but not 100% of carriers; some heterozygotes report inconsistent/mild flushing).
• Prevalence: Population allele frequency ~30–50% in East Asians (heterozygote + homozygote carriers together represent a majority of some East Asian populations); essentially 0% outside East Asian ancestry. ~540 million people worldwide are estimated carriers, i.e., roughly 8% of the world's population.
• Founder effect: Strong — the rs671 mutation is believed to derive from a single ancestral mutational event that arose in central China roughly several thousand years ago and spread with the expansion of rice-farming agricultural populations across East Asia (PMC9590465).
• Sex ratio: No strong sex-specific difference in the ALDH2 genotype itself, though phenotypic/behavioral consequences (e.g., drinking amount, cardiometabolic outcome risk) can differ by sex in cohort studies — e.g., a reported finding that women with high ALDH2*2 burden who drank ≥7 drinks/week had elevated diabetes/hypertension/cardiovascular risk relative to abstainers.
• Geographic distribution: Concentrated in China, Japan, Korea, and their diaspora populations; essentially absent in African, European, and most South/Southeast Asian and Indigenous American populations (with isolated historical reports of ALDH2 activity deficiency in some Indigenous South American groups needing separate genetic confirmation).
• Age distribution: Present from birth (germline variant); clinically manifest from first alcohol exposure onward across the lifespan.

10. Diagnostics

• Clinical/behavioral screening: Self-report flushing questionnaire — shown to correlate strongly with genotype (94–96% concordance in some validation studies) and is a widely used low-cost proxy for genotype in epidemiologic and even some clinical-counseling contexts (PMID:9419411).
• Ethanol/alcohol patch test: A validated cutaneous provocation test — a small ethanol-soaked patch is applied to the skin, and the resulting local flush is scored (including quantitative hue-saturation-value colorimetric analysis in newer studies) to predict ALDH2 genotype, particularly useful in adolescents/young people with little drinking history:

"Blinded genotyping showed inactive ALDH2 for 94.4% of subjects who reported always flushing... Genotype distribution... in subjects with positive ethanol patch test results was 5.9% for normal homozygote (NN), 82.4% for mutant heterozygote (NM), and 11.8% for mutant homozygote (MM)." (synthesis of patch-test validation literature)

• Genetic testing: Direct genotyping of ALDH2 rs671 (and optionally ADH1B rs1229984) via targeted SNP assay, PCR-RFLP, or as part of broader pharmacogenomic/consumer genomic panels — this is a single-variant test, not a gene panel or WES/WGS indication, since the causal variant is essentially the single well-characterized common polymorphism; the condition is listed in the NIH Genetic Testing Registry (C2674838) (GTR).
• Laboratory/biomarker confirmation: Direct or breath-based measurement of blood acetaldehyde concentration following a standardized alcohol challenge is the most direct biochemical confirmation, though it is primarily a research tool rather than routine clinical practice.
• Differential diagnosis: True IgE-mediated alcohol/ingredient allergy (e.g., to sulfites, histamines in wine/beer, or grape/grain proteins); carcinoid syndrome flushing; mast cell activation syndrome; rosacea exacerbation; pharmacologic disulfiram-like reactions from concurrent medications (metronidazole, certain cephalosporins, chlorpropamide); niacin flush. Genetic testing and the characteristic alcohol-dose-dependent, immediate-onset, tachycardia-associated presentation distinguish ALDH2-deficiency flush from these mimics.
• Screening applications: Endoscopic screening (esophageal iodine/Lugol staining) combined with ADH1B/ALDH2 genotyping has been used as a targeted esophageal-cancer surveillance strategy in high-risk (heavy-drinking, ALDH2-deficient) Japanese cohorts (PMC6328133).

11. Outcome / Prognosis

The acute reaction itself is not life-threatening in typical social-drinking doses and resolves spontaneously; however, ALDH2 deficiency carries substantial long-term morbidity risk conditional on continued alcohol exposure:

• Esophageal squamous cell carcinoma (ESCC): Strongest and best-replicated cancer association. A 2023 meta-analysis (23 studies) found rs671 was associated with altered ESCC risk (reported OR 0.60, 95% CI 0.50–0.73 for the variant in the additive/allelic model reported in that analysis), and multiple cohort studies confirm that low-activity ALDH2 combined with continued alcohol consumption substantially elevates ESCC risk relative to non-carriers or abstaining carriers (Zhang et al. 2023, Cancer Medicine, PMID:37795758; population cohort study, PMID:29707772).
• Other cancers: Associations reported with gastric cancer (PMC5731965), and studied (with more heterogeneous findings) in breast and ovarian cancer in East Asian women.
• Cardiovascular disease: Associations with hypertension, coronary vasospasm/myocardial infarction risk, atrial substrate remodeling and atrial fibrillation with modest alcohol consumption, and broader cardiometabolic risk factors in East Asian cohorts (PMC10986734 updated meta-analysis; PMC8615757 AF study; PMC4693762 hypertension case-control).
• Neurodegenerative disease: Emerging evidence that rs671 enhances amyloid-β pathology and may modulate Alzheimer's disease risk/cortical thickness patterns, though it is "not an independent risk factor for Alzheimer's disease" on its own (PMID:38519490).
• All-cause mortality: A Japanese population study found ADH1B and ALDH2 functional variants non-additively associated with all-cause mortality, implying complex interaction effects rather than simple linear dose-risk (PMC7028931).
• Protective/net-population effect: Because the reaction discourages heavy drinking in many carriers, ALDH2 deficiency is associated with substantially reduced rates of alcohol use disorder and alcoholic liver disease/cirrhosis at the population level — creating a genuine risk/benefit duality that a 2025 review frames explicitly:

"Beyond the Flush: Reframing ALDH2 Deficiency as a Public Health Risk" (Karger Public Health Genomics, 2025) — arguing the trait should be understood as a modifiable cancer/cardiovascular risk factor specifically in the (growing, per a 2025 AACR commentary) subset of carriers who drink despite the reaction, including in U.S./diaspora populations unfamiliar with the risk (AACR CEBP 2025, "ALDH2 Deficiency and Alcohol Intake in the United States: Opportunity for Precision Cancer Prevention").

• Notable emerging/exploratory association: A recent hypothesis-generating paper proposes the East Asian-specific rs671 polymorphism may partly explain the comparatively low incidence of Sudden Infant Death Syndrome (SIDS) in Asian infant populations, via an aldehyde-metabolism-related mechanism — this is a preliminary/associative hypothesis requiring further validation, not an established causal claim (ScienceDirect 2025).

12. Treatment

There is no approved disease-modifying or curative treatment; management is centered on avoidance, symptomatic care, and risk counseling.

• Primary management — behavioral/avoidance: Counseling to reduce or abstain from alcohol consumption is the mainstay, given the direct, dose-dependent link between continued drinking and cancer/cardiovascular risk in ALDH2-deficient individuals.
• Symptomatic pharmacotherapy: H2-receptor antagonists (e.g., famotidine) and H1-antihistamines have been used off-label/empirically by some individuals to blunt flushing (via effects on gastric ADH activity and vasodilation, respectively), though this is not recommended as a routine clinical strategy, since suppressing the aversive warning symptom while continuing to drink increases silent acetaldehyde exposure and associated cancer/cardiovascular risk — a point emphasized in the public-health-reframing literature above.
• Investigational/experimental — ALDH2 pharmacological activators: A major active research area involves small-molecule ALDH2 activators, most notably Alda-1 and newer analogs (e.g., AD-9308), which partially restore catalytic activity of the ALDH2*2 mutant enzyme:

"Alda-1 increases activity of wild-type ALDH21 and variant ALDH22 (by ~2-fold and 11-fold respectively), and is capable of partly restoring mutant ALDH2*2 activity, providing protection against cardiac ischemia." (search synthesis of pharmacology literature)

These compounds are being explored preclinically/clinically for indications including ischemic stroke/cardioprotection, alcohol use disorder (reducing acquisition/relapse of drinking in animal models), diabetic cardiomyopathy, and protection of hematopoietic stem cells in Fanconi anemia models exposed to aldehyde stress — not yet as an approved therapy for the flush reaction itself. A related ANS-6637 clinical protocol for alcohol use disorder targeting ALDH2 pharmacology has been registered (NCT03970109) (ClinicalTrials.gov protocol PDF). - Pharmacogenomic caution: Because the same enzyme system is pharmacologically inhibited by disulfiram, metronidazole, and certain cephalosporins/sulfonylureas, ALDH2-deficient individuals should be counseled that these drugs will produce an amplified, potentially more severe flush/tachycardia/hypotension reaction if alcohol is consumed concurrently. - Genetic counseling: Recommended in the context of pre-conception/family counseling primarily to inform risk communication about alcohol-related cancer risk rather than reproductive risk, since this is a common polymorphism rather than a rare severe Mendelian disorder.

Suggested NCIT terms: NCIT:C15240 (Genetic Counseling); NCIT:C15986 (Pharmacotherapy) with therapeutic_agent bound to a CHEBI/NCIT term for disulfiram or an investigational ALDH2-activator compound class; NCIT:C49236 (Therapeutic Procedure) for behavioral alcohol-avoidance counseling.

13. Prevention

• Primary prevention: Genetic/behavioral risk education — informing ALDH2-deficient individuals (identifiable via self-reported flushing history, patch test, or genotyping) that continued heavy alcohol consumption carries substantially elevated esophageal cancer and cardiovascular risk, and counseling toward abstinence or minimal intake. This is explicitly framed as an actionable precision-prevention opportunity in East Asian and diaspora populations unaware of their genetic status (AACR CEBP 2025).
• Secondary prevention/screening: Endoscopic surveillance with iodine (Lugol) chromoendoscopy in known ALDH2-deficient heavy drinkers, used clinically in Japan to detect early esophageal squamous neoplasia/dysplasia (PMC6328133).
• Population/public-health screening: Health education campaigns in Japan using the ethanol patch test in youth, specifically to identify ALDH2-deficient individuals before they establish drinking habits.
• Genetic screening: Not typically part of newborn or prenatal screening programs (this is a common, non-severe polymorphism rather than a serious early-onset Mendelian disorder), but is increasingly offered through consumer/direct-to-consumer genomics and can be incorporated into personalized alcohol-risk counseling.
• Public health/policy: Advocacy for greater clinician and public awareness of ALDH2 deficiency as a modifiable cancer risk factor, given its high prevalence and low current recognition outside East Asia (the 2025 AACR commentary specifically calls out the U.S. as an "opportunity for precision cancer prevention" given growing East Asian-American populations).
• Prophylaxis: No pharmacologic prophylaxis is currently recommended; suppressing symptoms with antihistamines/H2-blockers while continuing to drink is discouraged as a "false safety" strategy given the risk of masking, not eliminating, the underlying acetaldehyde exposure.

14. Other Species / Natural Disease

• Taxonomic scope: ALDH2 and the ethanol/acetaldehyde oxidation pathway are broadly conserved across mammals; however, the specific rs671/Glu504Lys inactivating polymorphism causing "acute alcohol sensitivity" is, per current evidence, specific to Homo sapiens (NCBITaxon:9606) and, within humans, largely restricted to East Asian ancestry populations.
• Naturally occurring analogous phenotype in other species: Search of the primate literature did not identify a well-characterized naturally occurring ALDH2-inactivating polymorphism in cynomolgus or rhesus macaques analogous to human rs671; primate alcohol-metabolism polymorphism research in these species has instead focused on CYP2E1 repeat-length variation, which does not recapitulate the human ALDH2-deficiency phenotype (PMID:11505041). This represents a genuine gap/negative finding rather than an established comparative model.
• Veterinary relevance: No established veterinary disease entity corresponding to this condition; not currently listed as a naturally occurring disorder in the veterinary/OMIA literature to the extent surfaced by this search.
• Comparative biology: The ALDH2 enzyme and its catalytic mechanism are highly conserved across vertebrates (used as the basis for cross-species structural/biochemical studies), supporting strong evolutionary conservation of the underlying detoxification pathway even though the specific human-deficiency allele is not shared with other species.
• Zoonotic potential: Not applicable — this is a non-infectious, purely genetic/metabolic condition.

15. Model Organisms

• Mouse (Mus musculus) — gene-targeted models:
• ALDH2 global/conditional knockout mice (Aldh2⁻/⁻): Show markedly higher blood acetaldehyde concentrations than wild-type after ethanol gavage or inhalational acetaldehyde exposure, with more severe toxic symptoms including weight loss; dramatically dampened energy expenditure/motility after ethanol; and near-complete voluntary alcohol avoidance in two-bottle-choice and drinking-in-the-dark paradigms — directly recapitulating the human aversive/protective-against-alcoholism phenotype (characterization paper, PMID:19874182; PMC4323349 review). Floxed conditional-knockout mice develop normally with no baseline phenotype absent alcohol/acetaldehyde challenge, confirming the trait is exposure-dependent, as in humans.
• ALDH2 E487K "humanized" knock-in mice (modeling the human dominant-negative Glu487Lys/Glu504Lys mutation): Used to study both acute acetaldehyde sensitivity and chronic consequences — e.g., the mutation "increases protein turnover and promotes murine hepatocarcinogenesis" (PNAS, PMID unlisted directly but described in search results), and human ALDH2*2 knock-in mice have been used to demonstrate that the ALDH2 activator Alda-1 protects against alcohol-derived esophageal DNA damage (Carcinogenesis, Oxford Academic).
• Applications: These models are used to study acute intoxication/toxicity thresholds, alcohol-avoidance behavior genetics, alcohol-related liver/gut-barrier injury (gut-liver axis endotoxemia models), esophageal/hepatic carcinogenesis, cardioprotection pharmacology (Alda-1/AD-9308 testing), and — via the digenic Aldh2/Adh5 double-knockout — hematopoietic stem cell genotoxic stress modeling relevant to AMeD syndrome.
• Model limitations: Mouse ALDH2 biology recapitulates the core biochemical lesion (acetaldehyde accumulation, aversive behavior) and several downstream consequences (hepatic, esophageal, cardiac), but species differences in ethanol pharmacokinetics, esophageal anatomy/carcinogen susceptibility, and social/behavioral drinking patterns mean the models do not fully capture the human socio-behavioral dimension of "drinking through the flush," nor the human population-genetic context of the rs671 founder allele.
• Other model systems: No major zebrafish, Drosophila, or C. elegans disease-model literature specific to this human-variant phenotype was identified in this search; cell-based/biochemical (recombinant ALDH2*2 enzyme kinetics) and structural-biology (X-ray crystallography of the tetramer) systems have been extensively used to define the dominant-negative mechanism at the protein level.

Suggested resources: MGI (Aldh2 knockout/knock-in mouse strain records); IMPC for systematic Aldh2 phenotyping data, if available.

Summary of Key Ontology Term Suggestions (verify exact CURIEs/labels via OAK/OLS before curation)

• MONDO: MONDO:0012454 (Alcohol Sensitivity, Acute)
• Genes (HGNC): hgnc:404 (ALDH2), hgnc:249 (ADH1B)
• HPO: HP:0031282 (Flushing), HP:0001649 (Tachycardia), HP:0001962 (Palpitations), HP:0002018 (Nausea), HP:0002315 (Headache), HP:0001324 (Muscle weakness)
• CHEBI: CHEBI:16236 (ethanol), CHEBI:15343 (acetaldehyde), CHEBI:15366 (acetic acid), CHEBI:27897 (disulfiram)
• UBERON: UBERON:0001043 (esophagus), UBERON:0002107 (liver), UBERON:0000948 (heart), UBERON:0001003 (skin epidermis)
• GO: GO:0006068 (ethanol catabolic process), GO:0004029 (aldehyde dehydrogenase [NAD+] activity), GO:0005759 (mitochondrial matrix)
• NCIT (treatment/procedure): NCIT:C15240 (Genetic Counseling), NCIT:C15986 (Pharmacotherapy), NCIT:C49236 (Therapeutic Procedure)

Notable Gaps / Areas Not Fully Resolved in Current Literature

• No approved pharmacotherapy that safely restores ALDH2 function in humans; Alda-1/AD-9308-class activators remain preclinical-to-early-clinical.
• No confirmed naturally occurring non-human animal model carrying an rs671-equivalent polymorphism (only engineered knock-in/knockout mice).
• The SIDS-protective hypothesis is preliminary and needs independent replication.
• Quantitative, standardized reference ranges for "diagnostic" blood acetaldehyde thresholds post-challenge are not well standardized across labs/populations.
• Long-term outcome data (cancer/cardiovascular/neurodegenerative risk) are drawn overwhelmingly from East Asian cohorts; risk quantification in diaspora/mixed-ancestry populations (e.g., US East Asian-American cohorts) is comparatively sparse, which the 2025 AACR commentary explicitly flags as a research and precision-prevention gap.

Sources

• Entry - #610251 - ALCOHOL SENSITIVITY, ACUTE - OMIM
• Clinical Synopsis - #610251 - OMIM
• Entry - #619151 - AMED SYNDROME, DIGENIC - OMIM
• ALDH2 variance in disease and populations — Disease Models & Mechanisms
• Alcohol Sensitivity, Acute — MalaCards
• Alcohol sensitivity, acute — NIH Genetic Testing Registry
• NM_000690.4(ALDH2):c.1510G>A (p.Glu504Lys) — ClinVar
• Uncovering newly identified aldehyde dehydrogenase 2 genetic variants — PMC11288122 / PMID:39075523
• Genetic influences on alcohol flushing in East Asian populations — BMC Genomics
• Combinations of alcohol-induced flushing with genetic polymorphisms — PMC8312924
• Origin and Spread of the ALDH2 Glu504Lys Allele — Phenomics
• Digenic mutations in ALDH2 and ADH5 cause AMeD syndrome — Science Advances / PMID:33355142
• Relationship between ESCC risk and ALDH2/ADH1B polymorphisms — meta-analysis, PMID:37795758
• Association of low-activity ALDH2 and alcohol consumption with esophageal cancer risk — PMID:29707772
• Alcohol Flushing, Alcohol and Aldehyde Dehydrogenase Genotypes, and Risk for ESCC — AACR CEBP
• ALDH2 Deficiency and Alcohol Intake in the United States — AACR CEBP 2025
• Beyond the Flush: Reframing ALDH2 Deficiency as a Public Health Risk — Public Health Genomics
• The ALDH2 gene rs671 polymorphism and cardiometabolic risk factors — updated meta-analysis, PMC10986734
• Variant ALDH2*2 as risk factor for LA substrate formation and AF — PMC8615757
• Associations between ALDH2 polymorphisms and hypertension risk — PMC4693762
• The aldehyde dehydrogenase 2 rs671 variant enhances amyloid β pathology — Nature Communications / PMID:38519490
• Structure of mitochondrial aldehyde dehydrogenase — Structure
• ALDH2(E487K) mutation increases protein turnover and promotes murine hepatocarcinogenesis — PNAS
• Reliability of a flushing questionnaire and the ethanol patch test — PMID:9419411
• Alcohol patch test with HSV-model analysis predicts ALDH2 genotype
• Endoscopic screening using esophageal iodine staining and ADH1B/ALDH2 genotypes — PMC6328133
• Characteristics of aldehyde dehydrogenase 2 (Aldh2) knockout mice — PMID:19874182
• Transgenic Mouse Models for Alcohol Metabolism, Toxicity and Cancer — PMC4323349
• Protective effects of Alda-1 on alcohol-derived DNA damage in esophagus of ALDH2*2 knock-in mice — Carcinogenesis
• Pharmacological activators of ALDH2 for alcohol use disorders
• Disulfiram — StatPearls, NCBI Bookshelf
• Disulfiram-alcohol reaction — Wikipedia
• Impacts of ADH1B rs1229984 and ALDH2 rs671 polymorphisms on risks of alcohol-related disorder and cancer — PMC9844601
• Functional variants in ADH1B and ALDH2 non-additively associated with all-cause mortality in Japanese population — PMC7028931
• A genetic polymorphism unique to East Asians, ALDH2 rs671, and SIDS incidence hypothesis — ScienceDirect 2025
• Examination of a CYP2E1 repeat polymorphism in a monkey model of alcohol abuse — PMID:11505041
• rs671 — SNPedia

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMC:PMC9844601 (abstract only): "The ALDH2 rs671 GA/AA genotypes significantly reduced the risk of alcohol-induced mental disorders by 87%, alcohol dependence syndrome by 83%, and alcohol abuse by 66%."
• closest text in source: "The results suggested that are reduction in alcohol consumption should be advised as a preventive measure for high-risk patients carrying ADH1B rs1229984 C or the ALDH2 rs671 A allele."
• PMID:9419411 (abstract only): "Blinded genotyping showed inactive ALDH2 for 94.4% of subjects who reported always flushing... whereas 95.6% of subjects reporting that they never exhibited facial flushing had active ALDH2"
• closest text in source: "Blinded genotyping showed inactive ALDH2 for 94.4% (102 of 108) of subjects who reported always flushing (early in their drinking history or currently) and for 47.7% (21 of 44) of those who reported sometimes flushing, whereas 95.6% (109 of 114) of subjects reporting that they never exhibited facial flushing had active ALDH2"
• DOI:10.1073/pnas.1510757112 (abstract only): "increases protein turnover and promotes murine hepatocarcinogenesis"
• closest text in source: "With this model, we show that murine ALDH2*2 increases ALDH2 protein turnover and promotes chemical-induced liver tumor development"